H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Basic information
- Product Name:
- H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT
- Synonyms:
-
- RPPGF
- ARG-PRO-PRO-GLY-PHE
- ARG-PRO-PRO-GLY-PHE ACETATE
- BRADYKININ (1-5)
- BRADYKININ FRAGMENT 1-5
- H-ARG-PRO-PRO-GLY-PHE-OH TFA
- H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT
- H-Arg-Pro-Pro-Gly-Phe-OH
- CAS:
- 23815-89-6
- MF:
- C27H40N8O6
- MW:
- 572.66
- Product Categories:
-
- Peptide
- Mol File:
- 23815-89-6.mol
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Chemical Properties
- Density
- 1.46±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- Soluble in DMSO
- pka
- 3.50±0.10(Predicted)
- form
- Solid
- color
- White to off-white
- Sequence
- Arg-Pro-Pro-Gly-Phe
MSDS
- Language:English Provider:SigmaAldrich
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Usage And Synthesis
Uses
Biologically active fragment of bradykinin
Biochem/physiol Actions
The bradykinin (BK) fragment (1-5) (RPPGF) is among the most stable of naturally occurring metabolites. It may be used as a marker for BK production in vivo. It is known that an intact Arg residue in the C-terminus is required for biological activities. BK 1-5 is the minimal peptide that inhibited α-thrombin-induced platelet aggregation and secretion and calcium mobilization. It also prevented α-thrombin from cleaving the thrombin receptor peptide, NATLDPRSFLLR, between arginine and serine. Such antithrombin activities of BK 1-5 may contribute to the cardioprotective nature of kinins.
in vivo
Bradykinin is a short-lived vasoactive peptide, with a reported half-life in vivo of 17 s, that is rapidly metabolized in the circulation to Bradykinin (1-5). Bradykinin (1-5), the product of two sequential cleavages of Bradykinin by ACE at the Pro7-Phe8 and Phe5-Ser6bonds, has been identified as the major stable metabolite of Bradykinin in vivo in human subjects, with a terminal half-life of minutes. Both Bradykinin and Bradykinin (1-5) inhibit α- and γ-thrombin-induced platelet aggregation (P<0.01 versus baseline). Bradykinin (1-5) inhibits γ-thrombin-induced platelet aggregation 50% at a calculated dose of 183±3 pmol/min. Neither Bradykinin nor Bradykinin (1-5) affects thrombin receptor-activating peptide-induced platelet aggregation, consistent with the hypothesis that Bradykinin and Bradykinin 1-5 inhibit thrombin-induced platelet aggregation by preventing cleavage of the thrombin receptor and liberation of thrombin receptor-activating peptide. Bradykinin (1-5) significantly attenuates α-thrombin-induced platelet aggregation but not TRAP 1-6-induced platelet aggregation. Bradykinin (1-5) potently inhibits γ-thrombin (500 nM)-induced platelet aggregation with an ED50 of 183±2 pmol/min[1].
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALTSupplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT(23815-89-6)Related Product Information
- ANGIOTENSIN I/II (4-8)
- ANGIOTENSIN II, HUMAN
- H-ARG-PRO-PRO-GLY-PHE-SER-PRO-OH ACETATE SALT
- H-MET-LYS-ARG-SER-ARG-GLY-PRO-SER-PRO-ARG-ARG-OH
- Angiotensin acetate
- ANGIOTENSIN I/II (1-6)
- ASP-ARG-VAL-TYR
- (DES-ASP1,ILE8)-ANGIOTENSIN II
- ANGIOTENSIN I/II (3-7)
- ABZ-GLY-4-NITRO-PHE-PRO-OH
- ANGIOTENSIN I/II (1-5)
- Angiogenin (108-122) TFA
- BRADYKININ (1-6)
- H-ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS-OH
- ANGIOTENSINOGEN (1-13) (HUMAN)
- (SAR1,ILE4,8)-ANGIOTENSIN II
- ANGIOTENSIN III, HUMAN
- ANGIOTENSIN 1/2 + A (2 - 8)